Neurodyn Acquires Memogain® for Dementia in Alzheimer’s Disease

Published: Sep 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany ( all assets related to their Alzheimer’s prescription drug candidate – Memogain®. Memogain® has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

Help employers find you! Check out all the jobs and post your resume.

Back to news